Support Center – FAQ

GBiowit offers a comprehensive portfolio of ready-to-use organoid culture media optimized for long-term expansion, differentiation, and maintenance of diverse organoid types. The portfolio covers 81 formulations across human, mouse, and monkey species, including:

• Complete (expansion) media — e.g. Human Intestinal Organoid Complete Medium (GBCM0021), Human Liver Organoid Complete Medium (GBCM0022), Human Pancreatic Organoid Complete Medium (GBCM0031), plus gastric, lung, airway, mammary, renal, corneal, skin, tongue, placental trophoblast, nasal mucosa, esophageal, gallbladder, endometrial, cervical, bladder, prostate, thyroid, ovarian and testicular organoid media.
• Tumor organoid media — covering colorectal, gastric, pancreatic, lung, breast, liver (HCC), cholangiocarcinoma, glioma, ovarian, cervical, prostate, nasopharyngeal, esophageal, bladder, thyroid, tongue, kidney (RCC), endometrial and gallbladder cancer models.
• Differentiation media — e.g. Human Intestinal Organoid Differentiation Medium (GBCM0044), Human Liver Organoid Differentiation Medium (GBCM0045), Human Airway/Lung/Nasal Mucosa Differentiation Media (GBCM0043/0046/0047), with matching mouse and monkey versions.
• Custom formulation service — available for rare organoid types or specific research needs; contact our technical team.

All media are sterile-filtered and lot-tested for pH (7.2–7.4), endotoxin (<10 EU/mL), biosafety (bacteria, fungi and mycoplasma negative) and organoid culture performance. See the full list on the Culture Medium category page.

Proper storage and handling are critical for maintaining bioactivity and reproducible organoid culture outcomes.

Storage conditions (per product datasheet):

• Unopened media: store at -20°C; valid for 6 months from the date of manufacture. Avoid repeated freeze-thaw cycles.
• Thawed / working aliquots: store at 2–8°C; valid for 2 weeks. Do not refreeze after thawing.
• Once thawed, use promptly; aliquot into working volumes if the full volume will not be used within 2 weeks.

Handling best practices:

1. Thaw frozen media at 4°C overnight; once thawed, mix by gentle inversion — do not vortex.
2. Pre-warm media to 37°C before adding to organoid cultures to avoid temperature shock.
3. Use aseptic technique; for primary tissue–derived organoids, antibiotics may be added during the first passages to prevent contamination.
4. Upon receipt, check for leakage or damage and store immediately at -20°C, or aliquot and keep at 2–8°C for near-term use.

Quality indicators: discard the medium if it appears turbid, shows precipitates, or changes color significantly (pH shift indicated by phenol red).

Transitioning organoids between medium formulations requires a gradual adaptation protocol to minimize osmotic shock, nutrient-gradient stress, and phenotypic drift:

1. Baseline assessment: document morphology, size distribution, and passage efficiency in the current medium (brightfield images, doubling time).
2. Prepare mixed media: Mix 1 = 75% old + 25% GBiowit medium; Mix 2 = 50%/50%; Mix 3 = 25% old + 75% GBiowit medium.
3. Passage 1 (Day 0): dissociate organoids into fragments using Dissociation Enzyme Solution I (GBOR0009), resuspend in Mix 1, and embed in ECM-gel Matrix (GBOR0013). Culture 5–7 days with medium changes every 2 days.
4. Passages 2–3 (Day 5–14): repeat dissociation and move to Mix 2, then Mix 3, monitoring morphology daily.
5. Full transition (Day 15–20): resuspend in 100% GBiowit medium and continue for at least 2 further passages to confirm stable growth kinetics.
6. Validation: assess viability (LIVE/DEAD), proliferation (Ki67), and lineage markers (e.g. Lgr5, Villin, Muc2 for intestinal organoids).

If viability drops below 70% during adaptation, extend one additional passage at the current mixture ratio before progressing.

Human Intestinal Organoid Complete Medium (GBCM0021) is formulated to recapitulate the intestinal stem-cell niche by combining growth factors, morphogens, and small molecules that activate Wnt, EGF and Notch signaling while suppressing BMP-driven differentiation:

• Wnt-pathway activation (Wnt3a + R-spondin-1): drives Lgr5+ intestinal stem cell self-renewal via the canonical β-catenin/TCF pathway and prevents Wnt-receptor turnover — essential for crypt budding and long-term expansion.
• Noggin (BMP antagonist): blocks BMP-induced differentiation into secretory lineages, maintaining the undifferentiated stem-cell pool over long-term passage.
• EGF: drives epithelial proliferation through EGFR activation and synergizes with Wnt/R-spondin signaling during the expansion phase.
• Small molecules: a TGF-β/Activin receptor inhibitor (e.g. A83-01 class) suppresses differentiation, and a p38 MAPK inhibitor reduces stress-induced apoptosis.
• Niche supplements: N-acetylcysteine (antioxidant protection in 3D culture) and nicotinamide (supports maturation during differentiation).

The combined formulation sustains Lgr5+ stem cells during expansion while preserving crypt–villus architecture and full multilineage differentiation capacity upon factor withdrawal. For formulation details and the Certificate of Analysis, contact GBiowit technical support.

Every production lot of GBiowit culture media passes a multi-step QC program before release:

• pH: 7.2–7.4
• Endotoxin: <10 EU/mL
• Biosafety: negative for bacteria, fungi, and mycoplasma detection
• Performance test: passed organoid culture test — reference organoid lines are cultured to verify establishment, expansion and morphology
• Sterile filtration of the final product

CoA access: the Certificate of Analysis for each lot — including lot number, manufacturing and expiration dates, storage conditions and QC results — is available on request. Contact GBiowit support with the catalog number (e.g. GBCM0021) and the lot number printed on the vial label. Extended stability data and GLP-grade documentation are available for custom formulations.

GBiowit offers a modular suite of organ-on-chip platforms designed for physiologically relevant organoid and cell culture under dynamic flow conditions. All platforms are supplied sterile (4 chips/box) and are compatible with standard inverted and confocal microscopy:

• GB Vascular Chip (GBOC0001) — induces self-assembly of vascular organoids and tumor organoids from pluripotent stem cells to build functional vascularized tumor models; supports immune-cell introduction for immune–vascular–tumor co-culture.
• GB Barrier Chip (GBOC0002) — dual-compartment chip with a porous membrane for epithelial/endothelial barrier models (gut, lung, BBB), supporting permeability and transport studies.
• GB Circular Perfusion Chip (GBOC0003) — continuous recirculating perfusion for long-term dynamic culture and shear-stress conditioning.
• GB Immune Co-culture Chip (GBOC0004) — designed for immune cell–organoid co-culture, immune migration and immuno-oncology assays.
• GB Microarray Chip (GBOC0005) — high-density microarray format for parallelized organoid culture and screening.
• GB Multifunctional Automated Cell Scanner (GBOC0006) — automated imaging instrument for label-free monitoring of organoid growth and morphology.

Storage: room temperature (15–25°C), protected from dust and physical damage; shelf life 12 months. Full specifications are on the Organ on Chip category page.

GBiowit's organ-on-chip platforms replicate key features of systemic physiology that static organoid monocultures cannot capture:

• Dynamic perfusion: the GB Circular Perfusion Chip (GBOC0003) provides continuous medium recirculation, mimicking blood flow, improving nutrient exchange, and applying physiologic shear stress that promotes endothelial and epithelial polarization.
• Vascularization: the GB Vascular Chip (GBOC0001) builds perfusable vascular networks within tumor organoid models, enabling drug delivery through a vessel-like route and supporting immune-cell recruitment studies.
• Barrier and transport crosstalk: the GB Barrier Chip (GBOC0002) models apical–basolateral compartmentalization for absorption and first-pass–style studies.
• Immune interaction: the GB Immune Co-culture Chip (GBOC0004) supports circulating immune cells interacting with organoid tissue, reproducing inflammation and immunotherapy-response readouts.

Combined with GBiowit's drug screening & pharmacology services and organ-on-chip & advanced model services, these platforms support ADMET-oriented study designs such as metabolite profiling, toxicity crosstalk detection, and disease modeling.

The protocol below describes a typical epithelial–endothelial co-culture on the GB Barrier Chip (GBOC0002); it can be adapted to other organ and cell combinations:

1. Chip preparation: remove the chip from its sterile packaging and inspect for defects. Pre-wet the channels with culture medium.
2. Matrix coating: inject diluted ECM-gel Matrix (Low GF, GBOR0012) to coat the porous membrane and incubate at 37°C until gelled.
3. Cell seeding: dissociate organoids into single cells or small fragments using Dissociation Enzyme Solution I (GBOR0009) (about 8 minutes at 37°C). Seed the apical channel with epithelial/organoid cells and the basolateral channel with endothelial cells.
4. Static attachment: culture statically for 24–48 hours with medium changes every 12–24 hours to form a confluent layer.
5. Perfusion: connect the chip to a perfusion setup (or use the GB Circular Perfusion Chip format) and ramp flow gradually to the target shear stress.
6. Monitoring: track barrier formation daily (TEER if instrumented, or FITC-dextran permeability), and validate tight junctions by immunofluorescence (e.g. ZO-1, claudin) before running transport or drug assays.

Detailed SOPs are provided with each chip; project-based setup support is available through our advanced model services.

GBiowit chips are fabricated from optically transparent, biocompatible materials selected for imaging quality and low small-molecule absorption, and are supplied sterile (4 chips/box, 12-month shelf life at 15–25°C):

• Optical compatibility: the chips are designed for standard inverted and confocal microscopy, live-cell imaging, and immunofluorescence endpoint analysis. Automated imaging can be performed with the GB Multifunctional Automated Cell Scanner (GBOC0006).
• High-content screening: the GB Microarray Chip (GBOC0005) provides a high-density array layout suited to automated imaging platforms and parallelized assays.
• Automation: chip formats follow standard laboratory handling conventions and are compatible with common liquid-handling workflows; our team can advise on integration with specific automation platforms.
• Low adsorption: material selection minimizes hydrophobic compound loss for drug-response and PK-oriented studies — a known limitation of PDMS-based prototyping chips.

For material datasheets and compatibility questions, contact GBiowit technical support.

Culture lifespan on-chip depends on the model type and perfusion conditions. Typical ranges observed for epithelial and organoid cultures are 1–3 weeks under continuous perfusion; optimized barrier models are usually assayed within 7–14 days once TEER/permeability stabilizes.

Key factors influencing longevity:

• Flow rate / shear stress: excessive shear detaches cells; insufficient flow limits nutrient exchange. Ramp flow gradually after seeding.
• Medium refresh rate: in recirculating setups (e.g. GB Circular Perfusion Chip), replace medium every 24–48 hours to prevent lactate accumulation and pH drop.
• Bubble management: use bubble traps and degassed medium; bubbles are a leading cause of channel failure.
• Matrix stability: basement-membrane coatings can degrade or contract over time; re-coating or supplementing with fresh ECM-gel Matrix (GBOR0013) extends culture life.
• Oxygen tension: high-density cultures may require increased oxygenation or lower flow-resistance layouts.

Monitoring cultures with the GB Multifunctional Automated Cell Scanner (GBOC0006) helps identify detachment or morphology drift early.

GBiowit offers two LDEV-free ECM-gel matrix formulations for organoid culture:

• ECM-gel Matrix (LDEV-Free) (GBOR0013) — standard basement-membrane matrix for general-purpose organoid embedding and expansion, providing native laminin/collagen IV/entactin-rich 3D support for most organoid types.
• ECM-gel Matrix (Low GF, LDEV-Free) (GBOR0012) — growth-factor–reduced version for applications where basal growth-factor signaling must be minimized: differentiation studies, defined-condition assays, drug screening, and mechanistic work.

Selection guide:

• Expansion of intestinal, gastric, pancreatic, liver and most epithelial organoids → ECM-gel Matrix (GBOR0013).
• Differentiation assays, dose-response studies, pathway analysis → Low-GF version (GBOR0012).
• Organ-on-chip coating (e.g. GB Barrier Chip) → Low-GF version (GBOR0012) diluted as a thin coating.

Both matrices are lot-tested for gelling performance and biological activity with reference organoid lines. If you are transitioning from Matrigel or another BME, see the transition FAQ below.

The two matrices differ in growth-factor content and intended application:

ECM-gel Matrix (LDEV-Free) (GBOR0013) — standard formulation:

• Contains the natural basement-membrane milieu of laminins, collagen IV, entactin and associated factors.
• Best for robust expansion, complex morphogenesis (budding, lumen formation), and establishing new organoid lines where maximal biological support is desired.

ECM-gel Matrix (Low GF, LDEV-Free) (GBOR0012) — growth-factor–reduced:

• Reduced basal levels of growth factors such as EGF, FGF, IGF and TGF-β, giving a more defined experimental baseline.
• Best for differentiation protocols, drug screening, signaling-pathway studies, and any assay where exogenous factor carry-over would confound readouts.

Rule of thumb: use the standard matrix (GBOR0013) for establishment and routine expansion; switch to the Low-GF matrix (GBOR0012) for differentiation, screening, and mechanistic assays. Both are LDEV-free and lot-validated for organoid culture.

Basement-membrane matrices are temperature-sensitive; improper handling causes premature gelling or loss of polymerization performance:

1. Thawing: thaw the vial overnight at 4°C or keep it on ice. Never thaw at room temperature or 37°C.
2. Keep cold: keep the matrix on ice at all times during preparation. Pre-chill tubes, pipette tips and plates at 4°C for 15 minutes before use.
3. Mixing: invert gently to homogenize — do not vortex; use wide-bore or pre-cooled tips to reduce shear.
4. Embedding (dome method): mix the organoid suspension with cold matrix on ice, dispense 30–50 µL domes per well (24-well), and polymerize at 37°C for 20–30 minutes before overlaying pre-warmed medium.
5. Thin-layer coating (e.g. chip or 2.5D culture): dilute in ice-cold medium, coat, incubate at 37°C, then remove excess before seeding.
6. Dilution: always use ice-cold medium; warm medium triggers gelation during mixing.
7. Storage: aliquot and freeze at -20°C or below per the product label; limit freeze-thaw cycles. Discard aliquots that gel in the tube or fail to gel after incubation.

Detailed handling instructions ship with each vial of GBOR0012 and GBOR0013.

Every lot of GBiowit ECM-gel matrix is released against a defined QC panel:

• Gelling performance: polymerization time and gel stiffness verified by gelation testing.
• Biological activity: organoid formation, budding and viability validated with reference organoid lines.
• Sterility and biosafety: tested for bacteria, fungi and mycoplasma; LDEV-free (lactate dehydrogenase–elevating virus negative) by screening.
• Endotoxin: controlled within specification.
• Protein concentration: measured per lot and reported on the Certificate of Analysis.

Because basement-membrane matrices are biologically derived, minor lot-to-lot variation is inherent. GBiowit manages it through large-pool manufacturing, per-lot QC normalization, and CoA reporting so that users can standardize dome volumes and seeding densities across lots. For fully defined assay conditions we recommend the Low-GF matrix (GBOR0012) and consistent lot reservation for longitudinal studies — contact us to reserve a single lot for your project.

A gradual matrix transition minimizes stress and preserves organoid morphology:

1. Recovery: release organoids from the current matrix (ice-cold buffer or Organoid Harvesting Solution (GBOR0007)) and wash with cold basal medium.
2. 50:50 adaptation: embed in a 1:1 mixture of the competitor matrix and GBiowit ECM-gel Matrix (GBOR0013). Culture for one passage (5–7 days).
3. 75:25 step: dissociate with Dissociation Enzyme Solution I (GBOR0009) and embed in 75% GBiowit matrix / 25% competitor matrix for a further passage.
4. Full transition: embed in 100% GBiowit ECM-gel matrix and culture at least one more passage before experimental use.
5. Validation: confirm morphology, viability and key markers (e.g. Lgr5, Ki67, Muc2 for intestinal organoids) against baseline records.

Troubleshooting: if domes detach, confirm plates are tissue-culture–treated and fully pre-chilled, and use the 50:50 mix for the first passage; if budding stalls, verify matrix gelling before embedding and review medium freshness.

GBiowit offers 66 ready-to-use organoid kits covering normal and tumor organoids across human and mouse tissues. Highlights include:

• Normal human organoid construction kits: intestinal (GBOK0019), gastric, cervical, lung, liver, breast, esophageal, endometrial, pancreatic, gallbladder and thyroid.
• Human cancer organoid construction kits: colorectal (GBOK0001), gastric, ovarian, cervical, lung, cholangiocarcinoma, breast, esophageal, testicular, endometrial, pancreatic, gallbladder, thyroid, nasopharyngeal, hepatocellular, prostate, kidney and bladder cancer.
• Mouse organoid construction kits: intestinal, gastric, lung, airway, liver, pancreatic, gallbladder, common bile duct, kidney, colonic, testicular, tongue and liver-cancer models.
• Expansion & differentiation kits: hepatic (GBOK0061) and intestine (GBOK0062) organoid expansion-and-differentiation kits.
• Specialty kits: organoid frozen-section embedding, Oil Red O / Nile Red lipid staining, free fatty acid assays, cancer-associated fibroblast culture, placenta, blood-vessel and cardiac maintenance kits.

Each kit is designed for tissue-to-organoid establishment with matched medium and reagents. Browse the full range on the Organoid Kit category page.

A typical GBiowit organoid construction kit provides the core consumables needed to establish organoids from tissue: organoid culture medium matched to the target organoid type, matrix/embedding support where applicable, tissue processing and washing solutions, dissociation reagents, and a step-by-step protocol booklet.

Commonly paired products (sold separately):

• Tissue Preservation Solution (GBOR0001) — keeps primary tissue viable during transport (recommended at sample collection).
• Dissociation Enzyme Solution I (GBOR0009) — routine passaging.
• ECM-gel Matrix (GBOR0013) — expansion embedding.
• Organoid Cryopreservation Medium (GBOR0008) — banking established lines.

Laboratory equipment required (user-supplied): biosafety cabinet, CO₂ incubator, inverted microscope, centrifuge, tissue-culture plates (24/48-well), sterile pipettes, conical tubes, PBS and basal washing medium.

Typical timelines from fresh tissue to a stable, passagable organoid culture:

• Intestinal / gastric epithelial organoids: first structures in 2–4 days; budding organoids ready for first passage in 5–7 days.
• Liver, pancreatic and most epithelial organoids: 7–14 days to first passage.
• Tumor organoids (PDO): initial growth in 5–10 days; 2–4 weeks to expand sufficient material for screening or biobanking, depending on tumor type and content.

Factors that influence success:

• Tissue quality and ischemia time: fresh tissue processed within a few hours gives the best results; Tissue Preservation Solution (GBOR0001) extends the viable transport window.
• Sterility: antibiotics are recommended for the first 1–2 passages with primary material.
• Tumor content and donor factors: viability and composition of the specimen affect establishment rates.
• Technique: first-time users typically improve after one or two practice runs; our protocols include troubleshooting guidance.

If a model fails to establish, GBiowit's organoid modeling & culture services can build the model for you.

The workflow below summarizes the standard protocol supplied with the Human Intestinal Organoid Construction Kit (GBOK0019):

1. Tissue collection: place fresh intestinal tissue immediately into ice-cold Tissue Preservation Solution (GBOR0001); wash and trim the mucosa into small (2–4 mm) fragments.
2. Crypt release: incubate fragments with the kit's chelating/dissociation buffer, then mechanically release crypts by vigorous shaking; filter through a 70 µm strainer and collect crypts by centrifugation (~200 × g, 3 min).
3. Embedding: mix the crypt suspension with ice-cold ECM-gel Matrix (GBOR0013) on ice; dispense 30–50 µL domes into pre-chilled wells and polymerize at 37°C for 20–30 minutes.
4. Culture: overlay pre-warmed Human Intestinal Organoid Complete Medium (GBCM0021). Spheroids typically appear by day 2, lumens by day 3–4, and budding organoids by day 5–7. Change medium every 2 days.
5. Passage: at day 5–7, dissociate with Dissociation Enzyme Solution I (GBOR0009) (8–10 min at 37°C) into 50–150 µm fragments and re-embed at a 1:3–1:6 split ratio.
6. Validation: fix in 4% PFA and immunostain for Lgr5, Ki67 and Villin to confirm stemness, proliferation and epithelial identity.

The full illustrated SOP is included in the kit; video walkthroughs are available from GBiowit support.

Organoids cryopreserve best as small fragments rather than single cells:

Freezing:

1. Passage organoids into 50–150 µm fragments using Dissociation Enzyme Solution I (GBOR0009); wash with cold basal medium.
2. Resuspend at 500–1,000 fragments/mL in ice-cold Organoid Cryopreservation Medium (GBOR0008).
3. Aliquot 1 mL into pre-chilled cryovials; place in a controlled-rate freezing container at -80°C for 24 hours (≈ -1°C/min), then transfer to liquid nitrogen for long-term storage.

Recovery:

1. Thaw rapidly in a 37°C water bath (60–90 seconds) until only a small ice crystal remains.
2. Dilute dropwise into ~10 mL pre-warmed basal medium; centrifuge at 200 × g for 3 minutes.
3. Resuspend in complete medium, embed in fresh ECM-gel Matrix (GBOR0013), and culture as usual. A ROCK inhibitor (e.g. Y-27632, 10 µM) for the first 24 hours improves post-thaw survival.

A 1–2 day recovery lag is normal; budding typically resumes by day 3–4. See the datasheet of GBOR0008 for validated recovery performance.

GBiowit's organoid reagent line covers the complete culture workflow — from tissue collection through expansion, passaging, harvesting, and banking:

• Tissue Preservation Solution (GBOR0001) — hypothermic preservation of primary tissue during transport.
• Tissue Washing Solution (GBOR0002) — cleaning primary tissue before processing.
• Tissue Fixation Solution (GBOR0003) — fixation for histology/IF endpoints.
• Organoid Washing Solution (GBOR0004) — routine washing of organoid cultures.
• Red Blood Cell (RBC) Lysis Buffer (GBOR0005) — removal of erythrocytes from tissue digests.
• Rinse Solution (GBOR0006) — general rinsing steps.
• Organoid Harvesting Solution (GBOR0007) — gentle, enzyme-free release of intact organoids from matrix for passaging, imaging or chip transfer.
• Organoid Cryopreservation Medium (GBOR0008) — optimized freezing of organoid fragments.
• Dissociation Enzyme Solution I (GBOR0009), II (GBOR0010) and III (GBOR0011) — graded enzymatic dissociation for routine passaging, finer fragmentation and single-cell preparation.
• ECM-gel Matrix (Low GF, LDEV-Free) (GBOR0012) and ECM-gel Matrix (LDEV-Free) (GBOR0013) — 3D embedding matrices.

All reagents are sterile-filtered and QC-tested; see the Organoid Reagents category page for datasheets.

Organoid Cryopreservation Medium (GBOR0008) is a ready-to-use freezing medium formulated to maximize post-thaw viability and preserve organoid morphology, stem-cell markers and function after long-term cryogenic storage.

Recommended usage:

• Preparation: thaw at 4°C or on ice; keep cold and use promptly. Do not heat above room temperature.
• Density: resuspend organoid fragments at approximately 500–1,000 per mL; very high densities reduce post-thaw recovery.
• Freezing: aliquot 1 mL into pre-chilled cryovials; use a controlled-rate container at -80°C for 24 hours (≈ -1°C/min), then transfer to liquid nitrogen.
• Thawing: 37°C water bath for 60–90 seconds; dilute dropwise into pre-warmed basal medium; centrifuge at 200 × g for 3 minutes; resuspend in culture medium and embed in fresh matrix. A ROCK inhibitor (10 µM Y-27632) for 24 hours post-thaw improves survival.

Storage: follow the product label (frozen, protected from repeated thawing); once thawed keep at 2–8°C and do not refreeze. Typical post-thaw results: organoids resume budding within 3–5 days and retain pre-freeze marker expression and functional properties.

Temperature, oxidation and repeated freeze-thaw cycles are the main threats to bioactivity. Recommended practices:

1. On receipt: check packaging for leakage or damage; store culture media immediately at -20°C (valid 6 months) or aliquot and keep at 2–8°C for use within 2 weeks.
2. Thawing: thaw overnight at 4°C; mix by gentle inversion — never vortex protein-containing liquids.
3. Aliquoting: split into single-use or weekly working volumes using low-protein-binding tubes; label with date and freeze-thaw count.
4. Freeze-thaw discipline: do not refreeze thawed medium; minimize freeze-thaw cycles for matrices and enzyme solutions.
5. During use: pre-warm medium to 37°C before feeding cultures; keep matrices and harvesting solutions on ice throughout handling; use aseptic technique.
6. Light-sensitive components: minimize light exposure of supplemented media (amber vials or foil where applicable).

Product-specific storage and validity are printed on each label and datasheet (e.g. media: -20°C/6 months, 2–8°C/2 weeks; ECM-gel matrices: frozen with limited freeze-thaw cycles; chips: 15–25°C, 12 months).

GBiowit provides graded dissociation and harvesting solutions matched to each step:

• Routine passaging (organoid fragments): Dissociation Enzyme Solution I (GBOR0009) — gentle enzymatic fragmentation to 50–150 µm pieces with high viability; typical incubation 8–10 minutes at 37°C with gentle agitation. Inactivate with cold basal medium containing serum or BSA and centrifuge at 200 × g.
• Finer dissociation / difficult matrices: Dissociation Enzyme Solution II (GBOR0010) — stronger digestion for dense or fibrotic organoids.
• Single-cell preparation (FACS, scRNA-seq, cloning): Dissociation Enzyme Solution III (GBOR0011) — optimized for single-cell suspensions; add DNase if clumping occurs, and keep times as short as possible to protect viability.
• Enzyme-free recovery of intact organoids: Organoid Harvesting Solution (GBOR0007) — releases intact organoids from matrix at 4°C for live imaging, transfer to organ-on-chip platforms, or downstream biochemistry where enzymes would interfere.

All four solutions are sterile-filtered and validated on reference organoid lines; detailed incubation times are on each datasheet.

Yes. There are two practical routes:

1. Start from a complete medium and adjust. GBiowit complete media (e.g. GBCM0021) are ready-to-use formulations that already contain the required growth factors, small molecules and supplements at optimized concentrations. Researchers commonly adjust conditions by:

• switching between expansion (complete medium) and differentiation medium versions (e.g. Human Intestinal Organoid Differentiation Medium, GBCM0044),
• adding pathway modulators (e.g. DAPT for Notch inhibition, Y-27632 for post-thaw recovery), and
• choosing the Low-GF matrix (GBOR0012) when a more defined baseline is needed for signaling or screening assays.

2. Request a custom formulation. For rare organoid types, defined-factor titrations, or GMP-aligned documentation, GBiowit's custom formulation service designs and manufactures medium to your specification. Contact technical support with your target organoid type and constraints.

Community-curated published formulations for many organ types are also available in our free Organoid Culture Medium Reference Library.

GBiowit's organoid modeling & culture services build custom organoid models from patient-derived tissue across a wide range of organs, matching our product coverage:

• Normal tissue models: intestine, stomach, liver, pancreas, kidney, lung/airway, mammary, esophagus, cervix, endometrium, gallbladder, prostate, thyroid, skin, cornea, nasal mucosa, tongue, placenta and more.
• Tumor (PDO) models: colorectal, gastric, pancreatic (PDAC), lung, breast, liver (HCC), cholangiocarcinoma, ovarian, cervical, endometrial, prostate, bladder, kidney (RCC), esophageal, nasopharyngeal, thyroid, tongue, glioma, gallbladder and testicular cancers.
• Genetic and disease models: e.g. COPD lung, endometriosis, vocal-cord leukoplakia and IBD-related models.

Sample requirements: fresh surgical resections, biopsies, or ascites/pleural effusion collected under IRB-approved protocols with informed consent. Ship tissue promptly in Tissue Preservation Solution (GBOR0001) at 2–8°C; our team provides a collection kit and shipping instructions upon project kickoff.

A typical custom organoid project runs 6–12 weeks from sample receipt to delivery:

1. Week 0–1 — Initiation: signed service agreement, project scope document, and shipment of a sample collection kit (including Tissue Preservation Solution (GBOR0001), cold packs and shipping instructions).
2. Week 1–3 — Establishment: tissue processing, organoid derivation and first passages; weekly progress updates with brightfield images.
3. Week 3–6 — Expansion & validation: scale-up, morphology review, marker validation (immunofluorescence/histology) and mycoplasma/sterility testing.
4. Week 6–8 — Characterization (per scope): targeted mutation confirmation, short-read sequencing or functional assays as contracted.
5. Week 8–12 — Delivery: cryopreserved vials in Organoid Cryopreservation Medium (GBOR0008) shipped on dry ice (live culture delivery optional), with SOPs covering passage protocols, medium recipes and troubleshooting.

Milestones and acceptance criteria are fixed in the project scope document before work begins.

Every custom model ships with a defined QA package:

• Identity & morphology: brightfield image series across passages and comparison with source-tissue histology where available.
• Marker validation: immunofluorescence or IHC for lineage and stemness markers appropriate to the model (e.g. Lgr5/Ki67/Villin for intestinal models).
• Genetic confirmation: targeted mutation verification or sequencing-based comparison with the donor tissue, per project scope.
• Safety testing: mycoplasma (PCR), sterility (bacteria/fungi) and endotoxin reporting.
• Growth characterization: doubling time, passage efficiency and recommended split ratios.
• Cryopreservation validation: post-thaw recovery test results from the banking lot (frozen in GBOR0008).

Extended characterization — RNA-seq, drug-response baselines, or on-chip integration — can be added through our drug screening and advanced model teams.

1. Submit an inquiry via the contact form or email info@gbiowit.com with the subject "Custom organoid modeling".
2. Provide project basics: organoid type (normal/tumor), tissue source and availability, disease background, intended application (screening, biobanking, mechanistic study), and any required characterization.
3. Scope call: our scientists schedule a technical discussion to confirm feasibility, sample logistics (including IRB/consent status), timeline and deliverables.
4. Quotation: a formal quote with milestones, acceptance criteria and pricing is issued — typically within 3–5 business days after the scope call.
5. Kickoff: upon agreement, we ship the sample collection kit (with Tissue Preservation Solution) and begin on sample receipt.

Helpful details to include upfront: tissue type and approximate amount, ischemia/transport conditions, prior culture attempts, and target model count.

Post-delivery support is included with every custom model:

• Documentation: full SOPs for thawing, passaging, medium preparation and banking, plus a troubleshooting guide.
• Technical hotline: direct access to the scientists who built your model for protocol questions — via email or scheduled calls.
• Recovery assistance: if post-thaw recovery under-performs the validated specification, we review your thawing records and re-ship replacement vials where the deviation is confirmed.
• Common issues and quick checks:
  • Slow recovery after thaw → verify controlled-rate freezing and rapid 37°C thaw; add 10 µM Y-27632 for 24 h.
  • Excessive differentiation → confirm expansion vs differentiation medium; verify matrix lot gelling.
  • Contamination → review aseptic practice; test for mycoplasma; use recommended antibiotics during early passages.

Long-term culture can also be handed back to GBiowit for maintenance, expansion or banking through our organoid biobanking services.

Our drug screening & pharmacology services support multiple assay formats matched to your study phase:

• 3D viability / cytotoxicity assays: ATP-based luminescence, resazurin, LDH release and caspase-3/7 readouts in 96- or 384-well organoid formats with multi-point dose-response curves (duplicates/triplicates plus vehicle controls).
• Barrier permeability assays: Transwell-format or GB Barrier Chip (GBOC0002) models with TEER monitoring and Papp calculation for absorption-oriented studies.
• Organ-on-chip PK/PD assays: perfused chip models with serial sampling for concentration-time profiling and metabolite analysis.
• Disease-model phenotypic screening: model-specific functional readouts (e.g. swelling assays for CF models, lipid accumulation for NAFLD, invasion for PDAC).
• Mechanism-of-action studies: reporter assays, phosphoprotein profiling and transcriptomic follow-up for confirmed hits.

Throughput scales from tens of compounds in pilot studies to automated high-throughput campaigns through our partner platforms; see the capacity FAQ below.

Reproducibility is engineered into every campaign:

• Standardized inputs: reference organoid lines expanded in GBiowit complete media and Low-GF ECM-gel Matrix (GBOR0012) for a defined assay baseline; lot-reserved reagents for longitudinal studies.
• Assay validation: Z'-factor qualification before screening (target ≥0.5 for biochemical and ≥0.4 for phenotypic assays); plate-level acceptance criteria.
• Controls and randomization: vehicle, positive-control and reference-compound wells on every plate; randomized compound mapping to control positional effects.
• Replication: technical replicates within runs and biological replicates across independent organoid batches; pre-defined hit-confirmation workflow with 4-parameter logistic curve fitting.
• Data integrity: raw data retention, audit-ready analysis pipelines and batch delivery of results with QC summaries.

Statistics (replicate counts, outlier rules, hit thresholds) are fixed in the study plan before the campaign starts.

Endpoints are selected per model and study goal:

• Viability & cytotoxicity: ATP content, resazurin reduction, LDH release, caspase-3/7 activation, live/dead imaging.
• Growth & morphology: organoid size distribution, budding ratio, automated brightfield tracking (e.g. with the GB Multifunctional Automated Cell Scanner, GBOC0006), invasion metrics.
• Functional endpoints: albumin/urea secretion and CYP450 activity (liver), TEER and transport (barrier models), beating parameters (cardiac models), hormone response (endocrine models).
• Molecular endpoints: viability-normalized biomarker panels, immunofluorescence quantification, reporter activity, transcriptomic and proteomic signatures.
• ADMET-oriented: permeability (Papp), efflux ratios, metabolite formation by LC-MS/MS in chip-based formats.

Custom endpoint development is available — discuss your readout with our pharmacology team.

Capacity depends on the assay format:

• Pilot / focused studies: tens to hundreds of compounds in 96-well 3D formats — typical turnaround 2–4 weeks including hit confirmation.
• Mid-size libraries (1,000–10,000 compounds): 384-well formats with automated liquid handling — typical turnaround 4–8 weeks with primary + confirmation screens.
• Large campaigns (10,000+ compounds): executed with our high-throughput partner platforms under GBiowit study design and QC — timeline scoped per campaign.
• Chip-based formats: lower throughput by nature (systems-level data); recommended for prioritized compound sets and mechanistic ADMET studies.

Compound management includes solubility checks in assay medium (DMSO ≤0.1%), precipitation flagging, and stability monitoring. Primary screening data are typically delivered within 24–48 hours of plate completion; confirmed-hit reports follow the agreed schedule.

Toxicity profiling uses organ-specific organoid and chip models with regulatory-aligned readouts:

• Hepatotoxicity (DILI): liver organoids — viability, albumin/urea function, CYP450 inhibition/induction, steatosis (Oil Red O; our Oil Red O Staining Kit, GBOK0046 supports in-house lipid readouts) and mitochondrial stress.
• Cardiotoxicity: cardiac models — beat rate/amplitude, structural biomarkers (e.g. troponin), supported by our Cardiac Organoid Maintenance Kit (GBOK0066).
• Nephrotoxicity: kidney organoids — injury markers and functional uptake assays.
• GI toxicity: intestinal organoids — barrier integrity (TEER/permeability), crypt toxicity and inflammatory cytokine release.
• Multi-organ systemic toxicity: interconnected chip models via our organ-on-chip & advanced model services for organ-crosstalk effects.

Standard panels run 7 days across ≥3 concentrations with histology, functional assays and biomarkers; extended chronic studies run 14–28 days. Reports can be formatted to support FDA/EMA-oriented submissions.

Through our organ-on-chip & advanced model services, GBiowit builds interconnected and vascularized model systems that go beyond static monocultures:

• Vascularized tumor models: built on the GB Vascular Chip (GBOC0001) — perfusable vessel networks within tumor organoids for drug-delivery and microenvironment studies.
• Immune–tumor co-culture models: on the GB Immune Co-culture Chip (GBOC0004) — circulating immune cells with organoids for immunotherapy response and inflammation studies.
• Barrier/absorption models: gut, lung and BBB-style barriers on the GB Barrier Chip (GBOC0002) for absorption and CNS-penetration oriented work.
• Dynamic perfusion models: on the GB Circular Perfusion Chip (GBOC0003) — long-term recirculating culture for chronic exposure and metabolite-accumulation studies.
• Custom multi-compartment systems: sequential organ compartments (e.g. intestine → liver) engineered per project for first-pass metabolism and crosstalk readouts.

Each system ships with validation data (viability, barrier/perfusion metrics, imaging) and SOPs.

Chip-based ADMET workflows combine experimental measurement with quantitative analysis:

1. Study design: define the ADMET question (absorption, metabolism, distribution, toxicity) and select the model configuration (barrier, perfused liver-competent module, or multi-compartment).
2. Experimental execution: dose via the physiologically relevant route (apical/perfusate), collect serial samples from each compartment, and monitor functional endpoints (TEER, viability, imaging).
3. Bioanalysis: LC-MS/MS quantification of parent compound and metabolites across time points.
4. Parameter estimation: derive Papp, efflux ratios, clearance estimates and concentration-time profiles; compare against literature or in-house reference datasets.
5. Modeling handoff: results are delivered in analysis-ready formats suitable for PBPK/IVIVE modeling by your computational team or ours.

Deliverables include the raw time-course data, calculated parameters, QC metrics and an interpretive report.

Barrier-focused assays on the GB Barrier Chip (GBOC0002) and Transwell-comparable formats include:

• Integrity assays: TEER monitoring (with compatible electrode setups), FITC-dextran paracellular permeability across molecular-weight ranges, and tight-junction immunofluorescence (ZO-1, occludin, claudins).
• Transport assays: transcellular permeability (Papp) classification for test compounds; bidirectional efflux assays for transporter substrates (P-gp/BCRP-style designs with specific inhibitors); nutrient and ion transport readouts where relevant.
• Quality controls: mass-balance verification (recovery >80%), time-course sampling, and reference-compound benchmarking on every run.

Typical applications: oral-absorption ranking, CNS-penetration screening, and formulation comparisons. Assays can be run as a service or set up in your lab with our chips and SOPs.

Custom chip projects typically run 8–16 weeks depending on complexity:

1. Week 0–2 — Design: requirement workshop, model configuration, and a written study plan with acceptance criteria.
2. Week 2–6 — Build: chip selection/preparation (e.g. GBOC0002, GBOC0003), cell/organoid sourcing or client-supplied material, and initial seeding/optimization runs.
3. Week 6–10 — Validation: barrier/perfusion metrics, baseline imaging, and reference-compound benchmarking.
4. Week 10–16 — Study execution & reporting: compound runs, bioanalysis, and the final report.

Deliverables: validated model with SOPs, raw and processed datasets, QC summaries, and an interpretive report. Optional: transfer of the established protocol to your lab, including chips and reagents.

Physiological relevance is verified at multiple levels before any study run:

• Structural fidelity: imaging-based confirmation of tissue architecture — polarized epithelia, continuous endothelial channels, expected marker distribution.
• Functional benchmarks: barrier tightness (TEER/permeability) against reference values; organ-specific functions (e.g. albumin secretion, CYP activity for liver modules); flow-response checks for vascularized models.
• Reference compounds: every validation includes known-permeability or known-toxicity compounds to confirm expected behavior.
• Reproducibility: inter-chip and inter-run variability quantified and reported; acceptance thresholds defined in the study plan.
• Documentation: complete QC metrics, raw data retention and audit-ready reporting.

Models that fail any acceptance gate are rebuilt before compound work begins.

GBiowit's organoid biobanking & research support services cover the full lifecycle of living biobanks:

• Banking: controlled-rate freezing in Organoid Cryopreservation Medium (GBOR0008) with two-tier master/working cell bank organization and liquid-nitrogen storage.
• Depositing: client lines accepted for secure storage, QC and redistribution under MTA; lines are re-validated on receipt (viability, mycoplasma, identity).
• Retrieval & distribution: cryopreserved vials shipped on dry ice with temperature logging, or live-culture delivery where feasible.
• Expansion services: large-scale expansion of banked lines for screening campaigns.

Line types span normal and tumor organoids across intestinal, gastric, liver, pancreatic, lung, breast, ovarian, kidney and other tissues — consistent with GBiowit's modeling coverage. Custom line generation plus banking can be combined in a single project.

Every banked line must pass a release panel at banking and before distribution:

• Viability & recovery: post-thaw viability and regrowth verified from a test thaw of each banking lot.
• Safety: mycoplasma-negative (PCR), sterility-tested, endotoxin within specification.
• Identity: donor-matched identity confirmation (STR/SNP-based comparison where reference material exists) and unique line coding with full traceability.
• Genetic stability: periodic karyotype/CNV review for long-term banks; passage limits documented per line.
• Phenotypic consistency: morphology scoring against reference images and, where contracted, functional marker checks.

QC certificates accompany every distributed vial.

Stability is protected by process design, not just testing:

• Two-tier banking: master and working banks minimize the passage distance between the original tissue and the end user (typically 1–3 passages).
• Defined culture conditions: expansion for banking uses GBiowit complete media and Low-GF ECM-gel Matrix (GBOR0012) to reduce selective pressure from undefined components.
• Scheduled surveillance: karyotype/CNV checks at defined passage intervals; morphology tracked with automated imaging comparisons against the reference bank.
• Functional spot-checks: lineage markers and model-specific functions re-verified at working-bank generation.
• Cold-chain control: validated shipping containers maintaining cryogenic temperatures with loggers; client post-thaw feedback collected for continuous monitoring.

Lines showing drift are retired or re-derived from earlier-passage stock.

Biobank users can access a menu of support services:

• Onboarding: line-specific SOPs, medium/matrix recommendations (e.g. matched culture media and ECM-gel Matrix), and optional hands-on training.
• Technical support: troubleshooting for thawing, passaging and assay adaptation via email or scheduled calls.
• Collaborative studies: joint grant applications, co-designed screening campaigns, and access to GBiowit's drug screening and chip platforms.
• Data resources: available characterization datasets (histology, markers, sequencing summaries) under the line's MTA terms.
• Custom work: line engineering (reporters, knockouts), expansion scale-up, and assay-ready plate preparation.

Academic collaborators benefit from dedicated pricing and publication-friendly MTA terms.

Ethical and legal compliance is built into the biobank's operating procedures:

• Informed consent: all human tissue is accepted only with documented donor consent covering organoid derivation, genetic analysis, and the intended use; withdrawal rights are respected.
• Ethics approval: IRB/ethics-committee approval is required from the originating institution; documentation is reviewed before accession.
• De-identification: donor identity is never stored with organoid data; lines carry coded identifiers with linkage keys held separately under access control.
• Regulatory compliance: procedures align with applicable privacy frameworks (e.g. GDPR, HIPAA where relevant) and Hong Kong's Personal Data (Privacy) Ordinance.
• MTA governance: deposits and distributions are governed by material transfer agreements defining ownership, permitted uses, publication obligations and IP terms.
• Biosafety: BSL-2 handling standards; dual-use concerns are reviewed before accepting engineered lines.

Our privacy policy describes website data handling; project-specific agreements govern research data.

An organoid is a 3D multicellular structure derived from stem cells or tissue biopsies that self-organizes to recapitulate key architectural and functional features of an organ.

Organoids maintain cell-cell and cell-matrix interactions, exhibit tissue-like architecture, and preserve genetic and phenotypic profiles better than 2D monolayers.

PDOs are established directly from patient tumor or normal tissue, retaining the histological and genomic characteristics of the original tissue.

Colorectal, gastric, pancreatic, lung, breast, liver, ovarian, prostate, and many others have been successfully modeled.

Basement membrane extracts like Matrigel or defined synthetic hydrogels are commonly used. The choice depends on the tissue type and application.

Typically 7–14 days for initial organoid formation; several weeks to expand for drug screening or biobanking.

Wnt3a, R-spondin, Noggin, EGF, FGFs, and BMP inhibitors are often used to maintain stem cell niches.

Yes, organoids are widely used for high-throughput drug sensitivity testing, toxicity profiling, and personalized medicine.

Trypan blue exclusion, ATP-based assays (CellTiter-Glo), live/dead staining, and morphological scoring are common methods.

A microfluidic device that recreates physiological tissue-level functions, often incorporating multiple cell types, perfusion, and mechanical forces.

They contain a porous membrane separating two compartments, allowing study of transport, permeability, and immune cell migration.

Yes, immune-organoid co-cultures are used to study immuno-oncology, inflammation, and infectious diseases.

Human-cell-based data, reduced cost, higher throughput, better control of variables, and alignment with the 3Rs principle.

A law allowing non-animal methods (organoids, MPS) in drug approval submissions, reducing reliance on animal testing.

Organoids are enzymatically or mechanically dissociated into fragments and re-embedded in fresh ECM.

With optimized protocols, success rates >80–90% are common for many carcinoma types.

Yes, CRISPR/Cas9, lentiviral transduction, and electroporation have been used to introduce mutations or reporters.

Spheroids are simple aggregates, while organoids self-organize with tissue-like architecture and contain multiple differentiated cell types.

Typically 12 months at -20°C; once thawed, use within 2 weeks at 2–8°C.

Yes, PDO drug sensitivity testing can guide individualized therapy, with >90% concordance seen in some studies.

Confocal, widefield, live-cell, and high-content screening can be used due to optical transparency.

Drugs are added to the donor compartment; samples from the receiver are collected over time to calculate Papp values.

Physiological shear stress (0.1-10 dyn/cm²) promotes endothelial and epithelial polarization and barrier function.

Yes, host-pathogen interactions including SARS-CoV-2, bacteria, and parasites have been studied on chip.

PDMS is common for prototyping; newer chips use low-absorption thermoplastics like COP or COC for drug studies.

From days to several weeks, depending on cell type and perfusion conditions.

Increasingly, with FDA Modernization Act, EMA reflection papers, and PMDA guidance supporting their use.

PDOs retain patient-specific mutations and heterogeneity; iPSC organoids are genetically defined and can model development.

Consider tissue origin, desired stiffness, growth factor content, and application (e.g., expansion vs. differentiation).

Yes, cryopreserved organoids can be shipped on dry ice; live cultures require specialized temperature-controlled packaging.

Sterility, endotoxin, pH, osmolality, and functional testing on standard organoid lines.

By withdrawing stem-cell maintenance factors and adding tissue-specific inducers (e.g., Wnt withdrawal, Notch inhibition).

Not yet entirely, but they are reducing and refining animal use, especially in early toxicity screening.

Organoids up to 500 µm in diameter are common; larger sizes may develop necrotic cores without perfusion.

Immunofluorescence, histology, RNA sequencing, and functional assays (e.g., CYP450 activity, TEER).

Multiple interconnected organ-on-chip modules that recapitulate systemic interactions and ADME profiles.

Yes, continuous perfusion and sampling enable real-time measurement of drug concentrations and metabolites.

Lack of vascularization, immune components, and stroma in standard models; these are being addressed with co-culture and chip approaches.

Organoid-derived cells may be used for transplantation or tissue repair; still mostly preclinical.

GMP-grade organoids are produced under strict quality controls for clinical applications, while research-grade is for lab use.

Brightfield imaging, size measurement, and metabolic assays (e.g., PrestoBlue). Automated systems enable real-time tracking.

Yes, liver-chip models predict hepatotoxicity with ~96% sensitivity vs. 67% for animal models in some studies.

Higher media and matrix costs, but reduced compound usage and higher clinical predictivity can offset expenses.

Cryopreservation in liquid nitrogen after controlled-rate freezing. Viability >90% is achievable with optimized protocols.

Yes, organoids have been used for pooled CRISPR screening to identify essential genes and drug resistance mechanisms.

Organoids are expanded and passaged in vitro, while ex vivo cultures maintain the original tissue architecture for a short period.

Typically ethylene oxide or gamma irradiation; some thermoplastics tolerate autoclaving.

Yes, cancer-associated fibroblasts (CAFs) can be incorporated to recapitulate tumor stroma.

A technique where cells are exposed to air on the apical side, used for lung and skin organoid models.

By controlling oxygen levels in the perfusion medium or using gas-permeable materials.

Some chips use as little as 1–10 µL of ECM per culture unit, minimizing reagent consumption.

Enzymatic digestion (TrypLE, dispase) or mechanical disruption; gentle protocols preserve viability.

Yes, SBS-format chips support high-content screening and robotic liquid handling.

Gravity-driven systems are simpler and pump-free; pump-based systems offer precise flow control.

Preclinical studies have explored transplantation of organoid-derived cells for liver, intestine, and pancreas repair.

AI enables automated segmentation, morphological classification, and drug response prediction from imaging data.

Yes, vascularized chips model intravasation, extravasation, and metastatic niche formation.

Organoids are self-assembled 3D tissues; organ-on-chip adds controlled microenvironment, perfusion, and mechanical cues.